12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AB103 regulatory update

FDA granted Fast Track designation for Atox Bio's AB103 to treat necrotizing soft tissue infections (NSTI)....

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >